Compass Therapeutics logo

Compass TherapeuticsNASDAQ: CMPX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 April 2021

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$227.02 M
-67%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-90%vs. 3y high
50%vs. sector
267.08
-19%vs. 3y high
96%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:42:10 GMT
$1.65+$0.04(+2.48%)

Dividend

No data over the past 3 years
$850.00 K-$13.08 M

Analysts recommendations

Institutional Ownership

CMPX Latest News

3 Penny Stocks With the Power to 10X Your $1K Investment
InvestorPlace24 March 2024 Sentiment: POSITIVE

Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.

Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research08 February 2024 Sentiment: POSITIVE

Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research14 November 2023 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Compass Therapeutics, Inc. (CMPX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

What type of business is Compass Therapeutics?

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

What sector is Compass Therapeutics in?

Compass Therapeutics is in the Healthcare sector

What industry is Compass Therapeutics in?

Compass Therapeutics is in the Biotechnology industry

What country is Compass Therapeutics from?

Compass Therapeutics is headquartered in United States

When did Compass Therapeutics go public?

Compass Therapeutics initial public offering (IPO) was on 05 April 2021

What is Compass Therapeutics website?

https://www.compasstherapeutics.com

Is Compass Therapeutics in the S&P 500?

No, Compass Therapeutics is not included in the S&P 500 index

Is Compass Therapeutics in the NASDAQ 100?

No, Compass Therapeutics is not included in the NASDAQ 100 index

Is Compass Therapeutics in the Dow Jones?

No, Compass Therapeutics is not included in the Dow Jones index

When was Compass Therapeutics the previous earnings report?

No data

When does Compass Therapeutics earnings report?

The next expected earnings date for Compass Therapeutics is 08 November 2024